24 October 2023 - BEAM Alliance

BEAM Alliance shares its views on the ongoing revision of the General Pharmaceutical Legislation

We call on policymakers to stop postponing decisions and either propose a clear incentive package now or reintroduce the TEE…

BEAM News
Member News
Events

Latest news of BEAM Alliance

24 October 2023 - BEAM Alliance

BEAM Alliance shares its views on the ongoing revision of the General Pharmaceutical Legislation

We call on policymakers to stop postponing decisions and either propose a clear incentive package now or reintroduce the TEE…

05 September 2023 - BEAM Alliance

BEAM Alliance is Launching a new Task Force to address Issues from the AMR Diagnostics Segment

The new Task Force is gathering innovative SMEs operating in the AMR field and external experts.

16 June 2023 - BEAM Alliance

BEAM’s reflection paper on the possible roles of DG HERA

The report represents an important step towards the implementation of a tangible solution to fix the AMR market. Although the…

23 May 2023 - BEAM Alliance

BEAM’s statement on the EU Council Recommendation on AMR

The proposal examines AMR in a rather exhaustive way. It includes provisions on the need to strengthen national action plans,…

13 March 2023 - BEAM Alliance

BEAM Alliance published its reflection paper calling for a fair evaluation of the Transferable Exclusivity Extension (TEE) voucher

BEAM Alliance proposes a hybrid model, in which innovation is rewarded by a Transferable Exclusivity Extension (TEE) voucher while, in…

17 February 2023 - BEAM Alliance

EFPIA-BEAM Rejoinder to “Transferable exclusivity voucher: a flawed incentive to stimulate antibiotic innovation”, The Lancet, 9 February 2023

The article presents several additional claims, a number of which require correction.

page 1/7

Tweets by alliancebeam

View twitter feed

Latest news of BEAM Members

13 November 2023 - Basilea

Basilea announces acquisition of fosmanogepix, a phase-3-ready broad-spectrum antifungal

Fosmanogepix is a potential first-in-class antifungal treatment candidate with a novel mechanism of action. It is available in intravenous and…

03 November 2023 - Infex Therapeutics Ltd

Infex: RESP-X successfully completes Phase I trial and initiates Phase IIa trial in NCFB patients

Across the four cohorts of our Phase I study, RESP-X has demonstrated a robust safety and PK profile, highlighting that…

31 October 2023 - Basilea

Basilea announces exclusive license and option agreement for potential first-in-class clinical-stage antibacterial agent

Basilea is a commercial-stage biopharmaceutical company founded in 2000 committed to discovering, developing and commercializing innovative drugs to meet the…

19 October 2023 - Basilea

Basilea announces acquisition of novel clinical-stage antifungal for treatment of Aspergillus mold infections

This is the first transaction in the implementation of our strategy to expand our clinical-stage anti-infectives pipeline and to complement…

17 October 2023 - Basilea

Basilea reports new data for ceftobiprole (Zevtera®) presented at US IDWeek Congress 2023

Ceftobiprole, the active moiety of the prodrug ceftobiprole medocaril, is an advanced generation cephalosporin antibiotic for intravenous administration, with rapid…

17 October 2023 - Destiny Pharma plc

Destiny Pharma: Publication of new microbiological data for XF-73

This peer‐reviewed publication demonstrates that XF‐73 has activity against all global staphylococcal strains tested that were obtained from patients who…

page 1/52

Events

18 March 2024

BIO-Europe Spring ® 2024 – 18th Annual International Partnering Conference

Reconnecting and facilitating global partnerships

06 March 2024

8th AMR Conference – Save the date!

The AMR conference is a platform for SMEs, start-ups, big pharma, academia, investors and public institutions to discuss strategies and…

16 November 2023

Emerging Antimicrobials and Diagnostics in AMR 2023 (EADA 2023)

EADA 2023 is the 11th AMR Insights International Matchmaking Symposium on row. The 1,5 day event provides an overview of…

06 November 2023

BIO-EUROPE 2023

BIO-Europe® is the preeminent partnering conference for the life sciences, bringing together international decision makers from the biotechnology, pharmaceutical and…

12 October 2023

REVIVE Webinar – Market interventions to improve access to antibiotics for resistant infections

This webinar will invite experts in market shaping, describe how market shaping interventions in other areas may be applied to…

27 September 2023

GARDP Webinar: Antibiotic shortages: causes, consequences, and solutions

The Global Antibiotic Research and Development Partnership (GARDP) is a Swiss not-for-profit organization developing new treatments for drug-resistant infections that…

20 September 2023

ChinaBio® Partnering Forum 2023

ChinaBio® Partnering Forum is the largest and most productive life science partnering conference in China.

20 September 2023

REVIVE Webinar – Clinical trials platforms for new and neglected antimicrobials

The Global Antibiotic Research and Development Partnership (GARDP) is a Swiss not-for-profit organization, registered under the legal name GARDP Foundation,…

07 September 2023

World AMR Congress

Since 2015, the World Anti-Microbial Resistance Congress has been the go-to conference globally for all stakeholders in the AMR space…

page 1/16